CAR T-cell Therapy for Solid Tumours – Application Prospects – 26 October 2021

  • Private Equity
  • Healthcare
  • Greater China


Former project manager at the Shenzhen Institute of Advanced Technology (SIAT) of the Chinese Academy of Science


  • Technical challenges of CAR-T cell therapy for solid tumours – tumour heterogeneity and microenvironment
  • Pancreatic, thyroid, gastric and liver cancer research, plus domestic and foreign players’ clinical progress
  • Costimulatory signal design and dual-targeting CAR-T design technical barriers
  • CAR-T cell therapy for solid tumours – development and clinical barriers, clinical trial protocol and endpoint design


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited